PCVX Q1 2025 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$181M

Net Income

-$141M

EPS (Diluted)

$-1.04

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$166M

Free Cash Flow

-$193M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$178M

Stockholders' Equity

$3.2B

Cash & Equivalents

$347M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$181M	-$114M	-57.9%
Net Income	-$141M	-$95M	-48.1%